SCHEDULE 13G/A: Panacea Venture Entities Disclose 2.6% Passive Stake in Amylyx Pharmaceuticals

Panacea Venture Healthcare Fund II, L.P. and its affiliated entities, including James Huang, have reported a 2.6% passive beneficial ownership stake in Amylyx Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• The filing is an Amendment No. 1 to a Schedule 13G, reporting beneficial ownership of Common Stock in Amylyx Pharmaceuticals, Inc.
• The reporting persons are Panacea Venture Healthcare Fund II, L.P., Panacea Venture Healthcare Fund II GP Company, Ltd., Panacea Innovation Limited, and James Huang.
• As of December 31, 2024, the reporting persons collectively beneficially own 2,200,000 shares of Amylyx Pharmaceuticals, Inc. Common Stock.
• This ownership represents 2.6% of the class, based on 85,688,365 shares outstanding as of January 13, 2025.
• All reporting persons share both voting and dispositive power over the 2,200,000 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, indicating a passive investment intent.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, providing no positive or negative operational or financial information about the issuer.

Positives

• The document itself, being a Schedule 13G, does not contain information typically categorized as 'positives' regarding the issuer's operational or financial performance. It solely reports beneficial ownership.

Negatives

• The document itself, being a Schedule 13G, does not contain information typically categorized as 'negatives' regarding the issuer's operational or financial performance. It solely reports beneficial ownership.

Risks

• The document does not detail specific operational or financial risks for Amylyx Pharmaceuticals, Inc. It is a disclosure of beneficial ownership.

Future Outlook

The document does not provide any forward-looking statements or guidance from Amylyx Pharmaceuticals, Inc. or the reporting persons regarding the issuer's future performance or strategic direction.

Management Comments

• James Huang, Founding Managing Partner of Panacea Venture Healthcare Fund II, L.P., Panacea Venture Healthcare Fund II GP Company, Ltd., and Panacea Innovation Limited, certified that 'to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

This filing indicates continued institutional investment interest in the pharmaceutical sector, specifically in Amylyx Pharmaceuticals. It reflects a passive investment strategy by Panacea Venture, a healthcare-focused fund, which is a common practice for venture capital firms holding stakes in publicly traded companies post-IPO.

Stakeholder Impact

• This filing primarily impacts shareholders by providing transparency on significant passive ownership stakes, confirming that a venture fund maintains a substantial, albeit passive, investment in the company.

Next Steps

• The reporting persons will be required to file further amendments to this Schedule 13G if there are material changes to their beneficial ownership percentage (e.g., an increase or decrease of more than 1% of the class).

Key Dates

Keywords

Amylyx Pharmaceuticals, Panacea Venture, Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment, healthcare fund